PIK3CA and breast cancer: Among metastatic BC patients, those with PIK3CA mutations had shorter PFS (median, 7.0 vs. 15.0 months; p = 0.022), and univariate Cox regression showed increased progression risk (HR = 2.16), although not significant after multivariate adjustment.